L eishmania, a genus of trypanosomatid protozoa, is endemic in 98 countries or territories worldwide, with infection transmitted by the bite of a female sand fly. The estimated yearly incidence of leishmania infection is 1.5 million cases of cutaneous leish ma ni a sis and 500,000 cases of visceral leish ma ni a sis. 1 Cutaneous leish ma ni a sis results from the parasitization of skin macrophages and generally is manifested as a papule that enlarges to a nodule that often ulcerates during a period of 1 to 3 months. Diverse leishmania species cause cutaneous leishma ni a sis. There are at least five species, including Leishmania major, on the Eurasian and African continents and seven species in the Americas. 1 Cutaneous leish ma ni a sis resolves without treatment in a few months to several years, with the period depending on the infecting species. For L. major, there was resolution of single lesions by 45 days of follow-up in approximately 20 to 45% of untreated patients in Tunisia or Iran, and approximately 70% had resolution of single lesions by 105 days. 2, 3 Despite these findings, cutaneous leish ma ni a sis can cause substantial morbidity owing to the continued presence of a skin ulcer and the psychological effect of disfigurement. 4 The World Health Organization (WHO) disability weight for cutaneous leish ma ni a sis is 0.023 (on a scale of 0 to 1, with increasing values reflecting more severe disease). This weight is greater than that for malaria-induced anemia (0.012) and similar to that for hookworm-induced anemia (0.024). 5 A variety of therapies for cutaneous leish ma nia sis exist and have been reviewed [6] [7] [8] [9] (19 in a systematic review by González and colleagues alone 6 ). Clearly, there remains a need for a treatment that is simple and efficacious with an acceptable side-effect profile. 10, 11 One nonsystemic treatment is the topical application of par o mo my cin-containing creams. Paro mo my cin is an antibacterial aminoglycoside that for unknown reasons also has efficacy against leishmania. The dose that is required to produce a 50% reduction in parasite load in in vitro samples is generally between 1 and 40 µg per milliliter. 12, 13 The maximum serum concentration is 23 µg per milliliter after intramuscular administration. 14 Intramuscular par o mo my cin cured visceral leish ma ni a sis in 95% of patients in India 15 but was less successful in those with cutaneous leish ma ni a sis. [16] [17] [18] To increase the amount of par o mo my cin that is delivered to the skin and parasites in these often-necrotic cutaneous lesions, 19 El-On and colleagues 20 created a formulation containing 15% par o mo my cin in white soft paraffin that also contained 12% methylbenzethonium chloride. This formulation was more effective than no treatment for L. major infection in Israel 21 and more effective than vehicle-control treatment for infection with L. mexicana and L. braziliensis in Guatemala. 22 However, cost and "severe irritancy and intolerance" associated with the use of 12% methylbenzethonium chloride, as seen in up to 75% of patients, 20 has resulted in the infrequent use of this formulation. 23-25 A cream containing 15% par o mo my cin in white soft paraffin plus 10% urea was sponsored by the WHO but was no more effective than vehicle control against L. major infection in Iran 3 and Tunisia. 2 We developed a cream containing 15% par omo my cin sulfate plus 0.5% gentamicin sulfate in a complex base (called WR 279,396) to aid drug penetration. Gentamicin was included in the formulation on the basis of efficacy studies in mice showing that gentamicin augmented the rate of cure and decreased the rate of relapse, as compared with par o mo my cin alone, particularly for species causing cutaneous leish ma ni a sis in the Americas. 26 Although gentamicin is not directly cytocidal to leishmania parasites, it may attenuate them, facilitating immunologic mechanisms of eradication through helper T-cell immunity. 27, 28 In addition, combination products may impart broad-range antibacterial activity against secondary bacterial infections that could otherwise delay wound healing, and such products may avert the development of resistance. In a previous phase 2 study, WR 279,396 was more effective than vehicle control against L. major infection 29 at the same site in Tunisia at which the WHO formulation was ineffective. 2 
Study Patients
Inclusion criteria included an age of 5 to 65 years; overall good health besides cutaneous leish mani a sis; if female, absence of pregnancy and lactation; and the presence of five or fewer lesions, with an index lesion that was ulcerative, measured 1 to 5 cm in diameter, and was confirmed to contain leishmania by means of culture or microscopical examination of lesion material. Exclusion criteria included clinically significant lymphadenopathy or mucosal involvement, against which a topical agent would not be expected to be effective. (See the Supplementary Appendix and the protocol for all eligibility criteria.)
End Points

Efficacy
We assessed efficacy by measuring the area of the cutaneous leish ma ni a sis lesion at baseline and at 20 days (completion of treatment), 28 days, 42 days, 49 days, 98 days, and 168 days (end of the study). For each lesion, protocol-specified measures of response were as follows: initial clinical improvement (reduction in the area of the index lesion by 50 to 99% at 42 days, as compared with baseline), initial clinical cure (complete reepithelialization [no ulcer present] at 42 days, or initial clinical improvement followed by 100% reepithelialization by 98 days), relapse (initial clinical improvement or cure followed by an increase in lesion size or reulceration by 168 days), and final clinical cure (initial clinical cure without relapse). The protocol-specified primary efficacy end point was the final clinical cure of an index lesion.
The protocol-specified definition of treatment failure was an absence of initial clinical improvement or cure or an absence of final clinical cure. In addition, withdrawal of the patient before the end of the study because either the patient or the investigator thought the lesion was unlikely to have a response constituted treatment failure, as did loss to follow-up.
Safety
The safety end points were adverse events and application-site reactions (i.e., patients' assessment of pain and irritation or clinicians' assessment of erythema, edema, and vesicles). Safety end points were assessed daily during therapy. Renal toxic effects and ototoxic effects from aminoglycoside exposure were ascertained by means of serum creatinine measurements at the end of therapy (at 20 days) and patients' daily reports of tinnitus and vertigo.
Statistical Analysis
The sample size of 375 patients was based on estimated rates of final clinical cure of 94% in the par o mo my cin-gentamicin group and 71% in the vehicle-control group, as shown in a previous study. 29 On the basis of these rates, a sample size of 125 patients in each of these two groups provided a statistical power of 99% to detect a significant difference in the rates of final clinical cure rates (94% vs. 71%). For powering the study, it was postulated that the cure rate in the par o mo my cin group would be between the rates in the par o momy cin-gentamicin group and the vehicle-control group.
The modified intention-to-treat population consisted of patients who received at least one dose of study treatment. We tested two hypotheses using a fixed testing-sequence procedure with an overall two-sided alpha level of 0.05 or less. The first null hypothesis was that there was no difference in the final clinical cure rate between par o mo my cin-gentamicin and vehicle control and there was no significant difference in the rate of a final clinical cure between the par o momy cin group and the vehicle-control group. The second null hypothesis was that there was no significant difference in the rate of a final clinical cure between the par o mo my cin-gentamicin group and the par o mo my cin group. A two-sided uncorrected chi-square analysis was used to test these hypotheses. Thus, the study was designed to determine whether par o mo my cin-gentamicin or paro mo my cin alone was superior to vehicle control and whether the combination product (par o mo my- Of the 1432 patients who were screened, 383 were randomly assigned to receive a study intervention. Owing to the logistics of moving study treatments to the field before the final eligibility determination was made, 8 patients underwent randomization but did not receive treatment because they were determined to be ineligible when they were scheduled to start treatment. The remaining 375 patients (125 in each of the three groups) received at least one application of a study treatment and were included in the modified intention-to-treat and safety analyses.
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cin-gentamicin) was superior to par o mo my cin alone (analytic details are provided in the Supplementary Appendix).
R e sult s
Patients
Of the 1432 screened patients, 383 were randomly assigned to receive a study treatment. A total of 375 received an investigational product and constituted the modified intention-to-treat population (Fig. 1) . Patient characteristics are shown in Table 1 and in the Supplementary Appendix. Approximately half the patients were male and adult. Patients had 1 to 5 lesions, and 58% had more than one lesion. The lesion size was significantly larger in the par o mo my cingentamicin group than in the other two groups. A total of 797 lesions were treated. Essentially all lesions were ulcerative. The majority of lesions were on the lower limbs, followed by the upper limbs, head, and torso. We determined the parasite species of 78% of the index lesions; all were L. major. Table 2 ). The next most common reason for failure was relapse, which generally consisted of enlargement by 49 days after initial improvement at 42 days. More patients had a relapse in each active-drug group than in the vehicle-control group (Table 2 ). There were eight withdrawals before a protocol-specified evaluation time point because the investigator or patient perceived an absence of response. Seven other patients withdrew for other reasons, did not complete therapy, or were lost to follow-up ( Fig. 1 and Table 2 ).
Although the protocol-specified primary end point was cure of the index lesion, the absence of a response in any lesion constitutes treatment failure for the patient. Therefore, the rate of cure of all lesions is of clinical interest. One patient in each of the active-drug groups and three patients in the vehicle group had a nonindex lesion that was not cured (Table 2 ). Therefore, 80% of patients receiving par o mo my cin-gentamicin and 81% of those receiving par o mo my cin alone had all lesions cured, as compared with 56% of patients receiving vehicle control (P<0.001 for both comparisons).
Although the protocol-specified criteria for cure (improvement at an early time point of 42 days, cure at an intermediate time point of 98 days, and no relapse by 168 days) are in accord with clinical practice, some clinicians may expect a treatment to provide a cure at an early time point. The percentage of all lesions that were 100% healed at 42 days were 79%, 83%, and 57% in the par o mo my cin-gentamicin, par o mo my cin, and vehicle-control groups, respectively (P<0.001 for each active-drug treatment group vs. the vehiclecontrol group) ( Table 2 ). The typical response of a lesion to treatment is shown in Figure 2 . The mean area of ulceration of the index lesion increased between 1 day and 20 days (the end of therapy) in the par o mo my cin-gentamicin group and in the par o mo my cin group but not in the vehicle-control group, with no withdrawals or treatment interruptions because of this reaction. By 28 days, however, the size of the mean lesion in the active-drug groups had decreased to approximately baseline levels.
Safety
All adverse events that were deemed by the investigators as at least possibly related to a study treatment were reactions of mild or moderate severity at the application site. Adverse events that occurred in at least 1% of patients in any group are shown in Table 3 . Erythema and skin irritation were present in all groups; the latter was attributed to the dressing. Minute vesicles were significantly more frequent in the active-drug groups than in the vehicle-control group. Superinfection (clinical signs of secondary bacterial infection of cutaneous leish ma ni a sis lesions) was significantly more common in the vehicle-control group than the active groups. One serious adverse event -acute poststreptococcal glomerulonephritis -occurred in the par o mo my cin-gentamicin group and was considered to be unrelated to the study treatment. the one nodular lesion. ‡ Of the eight patients who were withdrawn owing to disease progression, the patient in the par o mo my cin group was withdrawn by the investigator because of lymphangitis (suspected disease dissemination). The remaining seven patients were in the vehicle-control group: three were withdrawn by the investigator because the index lesion had increased in size by 28 days; one had index-lesion enlargement by a factor of 1.6 by 20 days, accompanied by development of three new lesions; two had index-lesion inflammation by 49 days; and one withdrew consent at 28 days because the index lesion had not changed in size. The effect of the lack of definitive end-point determination with respect to patients lost to follow-up was explored (see the Supplementary Appendix). § Complete reepithelialization occurred in significantly more lesions in either active group than in the vehicle-control group (P<0.001 for each comparison, by a two-sided uncorrected chi-square test).
There were no cases of clinically significant tinnitus or vertigo or changes in serum creatinine levels between screening and the evaluation at 20 days, and no patient was removed from the study owing to an adverse event. There were no deaths.
Discussion
This trial showed that either of two creams containing 15% par o mo my cin, one with and one without 0.5% gentamicin, was superior in efficacy to a vehicle-control cream for treating ulcerative cutaneous leish ma ni a sis caused by L. major in Tunisia. There was no advantage in the addition of gentamicin observed in this study. Topical Paromomycin for Cutaneous Leishmaniasis n engl j med 368;6 nejm.org february 7, 2013 531 no problems with compliance. We postulate that the inflammatory reaction aids ulcer resolution. Superinfection was more common with vehicle control than with par o mo my cin, which we attributed to an absence of local antibacterial effect of the aminoglycosides. All superinfections were treated with oral antibiotics and resolved.
This trial provides evidence that either par omo my cin formulation in the present hydrophilic vehicle control is an effective treatment for ulcerative L. major disease in Tunisia. Early treatment of L. major cutaneous leish ma ni a sis with a cream is simpler than the current treatment options for cutaneous leish ma ni a sis and follows the recent WHO recommendations for the treatment of L. major cutaneous leish ma ni a sis. 1 The similarity in the natural cure rate for L. major infection in such geographically separate areas as Tunisia 2 and Iran 3 suggests that either cream would be effective treatment for ulcerative L. major in general, although studies are needed to address this expectation. The efficacy of these creams against nonulcerative disease or disease caused by other species of leishmania remains to be fully investigated. In this regard, we note that in animals, par o mo my cin-gentamicin and par omo my cin alone were equally effective against L. major, a result that predicted the findings of our study, but par o mo my cin-gentamicin was more effective than par o mo my cin alone against American species such as L. panamensis and L. amazonensis. 26 For all cases of cutaneous leish ma ni asis, the therapeutic index for the two par o momy cin creams is enhanced by their acceptable side-effect profile, as compared with alternative interventions.
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